Terms: = Breast cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
83 results:
1. Presence of crown-like structures in breast adipose tissue; differences between healthy controls, brca1/2 gene mutation carriers and breast cancer patients.
Zwager MC; Holt-Kedde I; Timmer-Bosscha H; de Bock GH; Werker PMN; Schröder CP; van der Vegt B; Arjaans M
Breast Cancer Res Treat; 2024 Feb; 204(1):27-37. PubMed ID: 38057686
[TBL] [Abstract] [Full Text] [Related]
2. breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract] [Full Text] [Related]
3. Differences between zoledronic acid and denosumab for breast cancer treatment.
Ishikawa T
J Bone Miner Metab; 2023 May; 41(3):301-306. PubMed ID: 36879056
[TBL] [Abstract] [Full Text] [Related]
4. Increased Co-Occurrence of Pathogenic Variants in Hereditary breast and Ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
5. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with brca1 c.5096G>A (R1699Q) intermediate-risk variant.
Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K
Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850
[TBL] [Abstract] [Full Text] [Related]
6. breast tumor microenvironment structures are associated with genomic features and clinical outcome.
Danenberg E; Bardwell H; Zanotelli VRT; Provenzano E; Chin SF; Rueda OM; Green A; Rakha E; Aparicio S; Ellis IO; Bodenmiller B; Caldas C; Ali HR
Nat Genet; 2022 May; 54(5):660-669. PubMed ID: 35437329
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome in patients with primary epithelial ovarian cancer and germline brca1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract] [Full Text] [Related]
8. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract] [Full Text] [Related]
9. Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.
Rajan A; Nadhan R; Latha NR; Krishnan N; Warrier AV; Srinivas P
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188482. PubMed ID: 33260050
[TBL] [Abstract] [Full Text] [Related]
10. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome and toxicity from taxanes in breast cancer patients with brca1 and BRCA2 pathogenic germline mutations.
Bayraktar S; Zhou JZ; Bassett R; Gutierrez Barrera AM; Layman RM; Valero V; Arun B
Breast J; 2020 Aug; 26(8):1572-1582. PubMed ID: 32497289
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of breast cancer in carriers of brca1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
[TBL] [Abstract] [Full Text] [Related]
13. Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and clinical outcome in breast cancer.
Anwar SL; Sari DNI; Kartika AI; Fitria MS; Tanjung DS; Rakhmina D; Wardana T; Astuti I; Haryana SM; Aryandono T
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1223-1228. PubMed ID: 31030498
[TBL] [Abstract] [Full Text] [Related]
14. Prevalence and clinical outcomes of germline mutations in brca1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
[TBL] [Abstract] [Full Text] [Related]
15. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the iris study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
16. Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
Johnston SJ; Ahmad D; Aleskandarany MA; Kurozumi S; Nolan CC; Diez-Rodriguez M; Green AR; Rakha EA
BMC Cancer; 2018 Oct; 18(1):1027. PubMed ID: 30352570
[TBL] [Abstract] [Full Text] [Related]
17. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by brca1.
Qin T; Huang G; Chi L; Sui S; Song C; Li N; Sun S; Li N; Zhang M; Zhao Z; Li L; Li M
Biomed Pharmacother; 2017 Nov; 95():649-655. PubMed ID: 28881292
[TBL] [Abstract] [Full Text] [Related]
18. Genetic Versus Epigenetic brca1 Silencing Pathways: clinical Effects in Primary Ovarian cancer Patients: A Study of the Tumor Bank Ovarian cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
[No Abstract] [Full Text] [Related]
20. NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of breast cancer.
Ka NL; Na TY; Na H; Lee MH; Park HS; Hwang S; Kim IY; Seong JK; Lee MO
Cancer Res; 2017 May; 77(9):2453-2463. PubMed ID: 28249904
[TBL] [Abstract] [Full Text] [Related]
[Next]
